Anaplastic Astrocytoma - A Pipeline Analysis Report

Overview of the drug development pipeline for anaplastic astrocytoma

Anaplastic astrocytoma is a malignant brain tumor, which is caused by astrocytoma. Astrocytoma is mostly associated with certain hereditary issues including tuberous sclerosis, neurofibromatosis type I, and the LI-Fraumeni syndrome. People suffering from this tumor experience various symptoms including seizures, depression, focal neurological deficit, and headache. Technavio’s market research analysts have predicted that anaplastic astrocytoma market growth will be witnessed with the introduction of radiation therapy (RT) and chemotherapy as some of the most promising approaches to treat anaplastic astrocytoma, the global anaplastic astrocytoma market will witness growth in the forthcoming years.

According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the phase I development stage. For instance, sponsors such as Amgen developed AMG 595 and Boehringer Ingelheim developed Afatinib, which are under phase I stage. Our market research analysts have also identified that a small amount of drug molecules that are being developed comes under the pre-clinical, phase III, and phase II/III development stages. The pipeline landscape in the pipeline analysis report mentions the percentage of drug development molecules that are under the phase II stage.

Anaplastic astrocytoma industry analysis: Companies covered